Labcorp Oncology Engager | Digital Event

Labcorp_Oncology_ CROPPED

Risks, Dead-ends & Avoidable Delays: Optimising Preclinical Planning & Biomarker Targets to Maximise Clinical Development in Precision & Immuno-Oncology

FOR GERMAN AND AUSTRIAN-BASED ONCOLOGY DRUG DEVELOPERS

Thursday December 9, 2021 | 10.00am CET

Risks, Dead-ends & Avoidable Delays: Optimising Preclinical Planning & Biomarker Targets to Maximise Clinical Development in Precision & Immuno-Oncology

Precision and Immuno-Oncology drug development is being optimised through well-defined preclinical and clinical strategies focused on safety, endpoints and biomarker targets.  Evolutions in the regulatory framework, a deeper understanding of cancer and re-defining key endpoints for success in Immuno-Oncology and Precision Medicine are combining to de-risk development.

This Labcorp Oncology Engager has been created as an exclusive online event to provide C-level Executives, Heads of Development, Pre-clinical & Clinical Operations leaderships of German and Austrian Precision and Immuno-Oncology biotechs with key learnings and takeaways on trial design concepts and biomarker considerations for optimising development strategy, as well as Go / No-Go decisions for agents in the preclinical space, regulatory framework considerations and accelerating the development of new precision and IO therapies.

Join this Engager to identify emerging trends and best practices in achieving accelerated Immuno-Oncology and Precision drug development.

KEY TAKEAWAYS

  • Learn about specific issues in care in Germany, the reliance on radiation committees and the need to develop commercial strategies
  • Discover how a surge in digital healthcare technology can be included in product development and evidence generation
  • Hear about the importance of focusing on early disease diagnosis and management, and how Labcorp’s biomarker and CDx capabilities is well placed to help develop new products

 

Following a Q&A, attendees can connect with key Labcorp Oncology executives and members to converse and dig a bit deeper into the topics covered throughout the session.

EXPERT SPEAKERS

Bruce Hamilton

Director of Biopharmaceutical Development

Labcorp Oncology

Kenneth Morrison

Vice President, Regional Oncology Growth

Labcorp Oncology

Paul Baldrick

Executive Director, Nonclinical Regulatory Strategy, Product Development and Market Access Consulting

Labcorp Oncology

Ravi Karra

Senior Medical Director, Global Clinical Development

Labcorp Oncology

Wolfgang Schlaeger

Country Head, Director Clinical Operations, GCD Clinical Operations, Germany

Labcorp Oncology

ABOUT LABCORP ONCOLOGY

Labcorp Oncology believes in harnessing science to improve health and the lives of people with cancer. And so we work day and night, around the world, to support the delivery of more treatment options — whether you're a healthcare provider, pharmaceutical company, hospital, medical researcher or patient.

Learn about Labcorp Drug Development and Labcorp Oncology at www.drugdevelopment.labcorp.com and www.oncology.labcorp.com